Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib versus best available therapy in ruxolitinib-pretreated myelofibrosis
2018-003411-21Phase 3Active
- Sponsor
- Impact Biomedicines
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fedratinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF) (2 arms), sponsored by Impact Biomedicines. Primary endpoint: Spleen volume response rate. Started Mar 2019; status: active.
02
Drugs
fedratinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2018-003411-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003411-21.